GH Research PLC (GHRS)
GH Research develops mebufotenin-based treatments for depression and other psychiatric and neurological disorders. It last closed at $18.27 on Nov 17, down 2.56% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From GHRS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 5). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on GHRS in the past 90 days. The average target is $55.00, with a high of $55.00 and a low of $55.00, compared with the last close of $18.27.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | HC Wainwright & Co. | Target lowered | Buy | $65 → $55 |
| Aug 7 | Guggenheim | Maintained | Buy | $40 |
| Aug 7 | Cantor Fitzgerald | Maintained | Buy | $40 |
| Aug 6 | Needham | Maintained | Buy | $39 |
| Jul 27 | Wells Fargo | Initiated | Buy | $44 |
Technical Analysis
The stock is 6% below its 20 day and 20% below its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 39). The nearest support is the swing low (Nov 6) at $18.16, and the nearest resistance the Pivot R1 at $18.63.
| RSI (14) | 38.52 | Weak, oversold below 30 | Neutral |
| MACD | -0.79 | Above its signal line | Bullish |
| Stochastic | 20.5 | Middle of its range | Neutral |
| ADX (14) | 18.5 | No clear trend | |
| Williams %R | -84.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -110.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −9.9% | Change over 10 sessions | Bearish |
| ATR (14) | $1.27 | Typical daily range, 6.9% of price |
| RSI (14) | 39.75 | Weak, oversold below 30 | Neutral |
| MACD | -0.92 | Below its signal line | Bearish |
| Stochastic | 8.3 | Near the bottom of its range | Oversold |
| ADX (14) | 31.8 | Trending down | |
| Williams %R | -94.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -109.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −32.8% | Change over 10 sessions | Bearish |
| ATR (14) | $2.92 | Typical daily range, 16.0% of price |
What happened before
See how GHRS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How GHRS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in GHRS in the last 90 days.
GHRS Institutional Ownership
Full report →- ▲47 buying vs 23 selling
- ▼Shares held by funds -1.3%
- ▲Funds holding +17
- ▲Superinvestors: 3 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 80 | 63 | +27.0% |
| In funds' top 10 | 3 | 3 | 0.0% |
| Held by funds | – | – | – |
| New / increased | 22 / 25 | 17 / 18 | +34.3% |
| Reduced / sold out | 18 / 5 | 16 / 9 | −8.0% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GHRS is in one of them and how their past GHRS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GHRS in an article yet. Here's the latest on the wider market.
About GH Research
GH Research is a biopharmaceutical company based in Dublin, Ireland, that is developing treatments for psychiatric and neurological disorders. Its product candidates are based on mebufotenin, studied as an inhaled treatment called GH001 and as an intravenous treatment called GH002. The company's initial focus is treatment resistant depression, a form of major depressive disorder in which patients have not responded adequately to standard therapies. It has not yet received approval to sell any product, and its intended customers are patients with depression and the healthcare providers who treat them.
- Headquarters
- Dublin 2, Ireland


